Ark Therapeutics Group plc

Marketing deal signed with Teva Medical for Kerraboot in Israel

Published in Medical Device Business Week, September 29th, 2004

Ark Therapeutics Group plc announced that it has signed a 10-year exclusive marketing deal with Teva Medical, Ltd., a subsidiary of Teva Pharmaceutical Industries, Ltd., (TEVA) for the sale and distribution of Kerraboot in Israel.

The novel wound management device for leg and foot ulcers will be marketed by Teva Medical to all sectors of the healthcare community in Israel. The terms of the deal include an undisclosed upfront payment to Ark, minimum annual order levels and profits from commercialization being shared between the two companies.

It is estimated that lower leg and foot ulceration affects 1% of the adult population in the developed world1...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Device Business Week

Source: Medical Device Business Week (2004-09-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry